GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » 12-1 Month Momentum %

Galmed Pharmaceuticals (Galmed Pharmaceuticals) 12-1 Month Momentum % : -92.58% (As of May. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-12), Galmed Pharmaceuticals's 12-1 Month Momentum % is -92.58%.

The industry rank for Galmed Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:

GLMD's 12-1 Month Momentum % is ranked worse than
96.43% of 1486 companies
in the Biotechnology industry
Industry Median: -22.355 vs GLMD: -92.58

Competitive Comparison of Galmed Pharmaceuticals's 12-1 Month Momentum %

For the Biotechnology subindustry, Galmed Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galmed Pharmaceuticals's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's 12-1 Month Momentum % falls into.



Galmed Pharmaceuticals  (NAS:GLMD) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galmed Pharmaceuticals  (NAS:GLMD) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Galmed Pharmaceuticals 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Galmed Pharmaceuticals (Galmed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
16 Tiomkin Street, Tel Aviv, ISR, 6578317
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Galmed Pharmaceuticals (Galmed Pharmaceuticals) Headlines